Keenova Therapeutics and Par Health
The Chemist III role involves performing quality control laboratory chemical analyses of raw materials, in-process materials, stability, and finished products to support pharmaceutical manufacturing and process validation. The position requires conducting complex analyses, troubleshooting instrumentation, and participating in regulatory compliance efforts.
Keenova Therapeutics and Par Health are the successor entities formed after Mallinckrodt's merger with Endo; Keenova Therapeutics focuses on specialty therapeutics across rare and unaddressed conditions (immunology, urology, hepatology, ophthalmology, orthopedics, critical care), while Par Health develops high-quality generics, sterile injectables, and active pharmaceutical ingredients (APIs) with a robust U.S.-advantaged manufacturing network.
Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader
Aug 1, 2025
With merger in the books, Mallinckrodt and Endo rebrand as Keenova and spin off Par Health
Nov 11, 2025
Judge Says 'Error' Kept Mallinckrodt Execs In Investor Suit
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Keenova Therapeutics and Par Health.
Mallinckrodt Names Christiana Stamoulis President and CFO
Aug 6, 2025